Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
- Mechanism
- Curator reviewed
Bimoclomol binds to HSF-1 and induces a prolonged binding of HSF-1 to the respective DNA elements. Since HSF-1 does not bind to DNA in the absence of stress, the bimoclomol-induced extension of HSF-1/DNA interaction may contribute to the chaperone co-induction of bimoclomol observed previously. These findings indicate that bimoclomol may be of value in targeting HSF-1 so as to induce up-regulation of protective Hsp-s in a non-stressful manner and for therapeutic benefit.
- Primary indication
- Investigated for use/treatment in neuropathy (diabetic) and wounds.Curator reviewed
- Formula / weight
- C14H20ClN3O2 · 297.781 g/mol (avg)
- Code names
- ABT-822 · BRLP-42
Resolves to
NMOVJBAGBXIKCG-VKAVYKQESA-NSMILESOC(CO\N=C(/Cl)C1=CN=CC=C1)CN1CCCCC1What you can answer from here — as of March 06, 2025
Which drugs share a target with Bimoclomol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account